# SPAG9

## Overview
SPAG9, or sperm-associated antigen 9, is a gene that encodes a protein involved in various cellular processes, particularly within the mitogen-activated protein kinase (MAPK) signaling pathway. The SPAG9 protein is a member of the JNK-interacting protein (JIP) family and is characterized by its structural domains, including a JNK-binding domain, leucine zipper, coiled-coil, and transmembrane domains, which facilitate its role as a scaffold protein. This protein is predominantly expressed in the testis, where it plays a crucial role in sperm-egg interaction during fertilization, specifically localizing to the acrosomal compartment of spermatozoa. Beyond its reproductive functions, SPAG9 is implicated in various cancers, where it influences cell proliferation, differentiation, and apoptosis through its interactions with JNK1, JNK2, and JNK3. Its expression levels and interactions in cancerous tissues suggest its potential as a biomarker and therapeutic target in oncology (JAGADISH2005Characterization; Garg2009Sperm‐associated).

## Structure
The SPAG9 protein, also known as sperm-associated antigen 9, is characterized by its structural homology with c-Jun N-terminal kinase (JNK)-interacting proteins. The primary structure of SPAG9 consists of 766 amino acids, with a monoisotopic mass of approximately 83.9 kDa (JAGADISH2005Characterization). The secondary structure is predominantly α-helical, as confirmed by circular dichroism (CD) spectra, which indicate a helical content of 40.2% (JAGADISH2005Characterization).

SPAG9 contains several key domains, including a JNK-binding domain (JBD), a leucine zipper motif, an extended coiled-coil domain, and a transmembrane domain (JAGADISH2005Characterization). These domains are crucial for its function, particularly in dimerization and interaction with JNK proteins (JAGADISH2005Characterization). The leucine zipper and coiled-coil domains facilitate the protein's aggregation and proper localization (JAGADISH2005Characterization).

SPAG9 exhibits anomalous migration on SDS/PAGE, likely due to strong hydrophobic interactions involving its leucine zipper, transmembrane domain, and coiled-coil structures (JAGADISH2005Characterization). The protein is specifically expressed in the testis and plays a role in spermatozoa-egg interaction, with localization to the acrosomal compartment of spermatozoa (JAGADISH2005Characterization).

## Function
SPAG9 (sperm-associated antigen 9) is a protein involved in several critical cellular processes, primarily through its role in the JNK signaling pathway. This protein is structurally related to the JIP (JNK-interacting protein) family and interacts specifically with JNK1, JNK2, and JNK3, but not with other MAPKs like ERK2 or p38α (JAGADISH2005Characterization). SPAG9 contains domains such as the JNK-binding domain, coiled-coil, leucine zipper, and transmembrane domains, which are essential for its dimerization and proper localization within the cell (JAGADISH2005Characterization).

In healthy human cells, SPAG9 is expressed predominantly in the testis, where it plays a role in sperm-egg interaction during fertilization. It is localized specifically on the acrosomal compartment of human spermatozoa and is retained on the equatorial segment after the acrosome reaction, indicating its involvement in sperm capacitation and fertilization (JAGADISH2005Characterization). The protein's ability to form oligomeric complexes is crucial for its function in the JNK signaling pathway, which influences cell proliferation, differentiation, and apoptosis (JAGADISH2005Characterization). These molecular activities highlight SPAG9's significance in reproductive processes and cellular communication.

## Clinical Significance
Alterations in the expression of the SPAG9 gene have been implicated in various cancers. In cervical cancer, SPAG9 is highly expressed in 82% of cases and is associated with tumor grades, suggesting its potential as a biomarker for early detection and diagnosis (Garg2009Sperm‐associated). The down-regulation of SPAG9 using small interfering RNA (siRNA) has been shown to significantly inhibit cervical tumor growth and metastasis, indicating its role in tumor progression and as a potential therapeutic target (Garg2009Small).

In epithelial ovarian cancer (EOC), SPAG9 is expressed in 90% of tissues, regardless of disease stage, and is linked to tumor aggressiveness and metastasis, particularly in p53 mutant-type tumors (Garg2007SpermAssociated). Its immunogenicity makes it a promising candidate for early detection and immunotherapy in EOC (Garg2007SpermAssociated).

SPAG9 is also upregulated in osteosarcoma, where its knockdown reduces cell motility, invasion, and angiogenesis, suggesting its involvement in metastasis (YANG2015SPAG9). In chronic myeloid leukemia (CML), SPAG9 is expressed in 88% of patients, with a significant humoral response, highlighting its potential as a biomarker and therapeutic target (Kanojia2010Sperm).

## Interactions
SPAG9, also known as sperm-associated antigen 9, is involved in several protein interactions, particularly within the mitogen-activated protein kinase (MAPK) signaling pathway. It interacts with c-Jun N-terminal kinases (JNKs), specifically JNK1, JNK2, and JNK3, with a higher affinity for JNK2 and JNK3 compared to JNK1. This interaction is facilitated by the JNK-binding domain (JBD) of SPAG9, which is crucial for its binding to these kinases. SPAG9 does not interact with other MAPKs such as ERK2 or p38α (JAGADISH2005Characterization).

In the context of cancer, SPAG9 has been shown to interact with components of the MAPK pathway, influencing cell proliferation and apoptosis. In liver cancer, SPAG9 interacts with JNK and affects the expression of MKK3, a kinase upstream of p38, although it does not alter MKK6 levels (Luo2019SPAG9MKK3p38). In Kaposi's sarcoma, SPAG9 is upregulated by the viral interferon regulatory factor 1 (vIRF1), which enhances its interaction with JNK1/2 and promotes VEGFA transcription, contributing to angiogenesis and tumorigenesis (Li2020Sperm). These interactions highlight SPAG9's role as a scaffold protein in the JNK signaling pathway, impacting various cellular processes.


## References


[1. (Kanojia2010Sperm) Deepika Kanojia, Manoj Garg, Shikha Saini, Sumit Agarwal, Rajive Kumar, and Anil Suri. Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia. Leukemia Research, 34(7):858–863, July 2010. URL: http://dx.doi.org/10.1016/j.leukres.2010.01.017, doi:10.1016/j.leukres.2010.01.017. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.leukres.2010.01.017)

[2. (Luo2019SPAG9MKK3p38) Shudi Luo, Biqiong Ren, Guoying Zou, Junlong Liu, Wei Chen, Yiran Huang, Xing Chen, and Yin Fu. Spag9/mkk3/p38 axis is a novel therapeutic target for liver cancer. Oncology Reports, January 2019. URL: http://dx.doi.org/10.3892/or.2019.6987, doi:10.3892/or.2019.6987. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/or.2019.6987)

[3. (JAGADISH2005Characterization) Nirmala JAGADISH, Ritu RANA, Ramasamy SELVI, Deepshikha MISHRA, Manoj GARG, Shikha YADAV, John C. HERR, Katsuzumi OKUMURA, Akiko HASEGAWA, Koji KOYAMA, and Anil SURI. Characterization of a novel human sperm-associated antigen 9 (spag9) having structural homology with c-jun n-terminal kinase-interacting protein. Biochemical Journal, 389(1):73–82, June 2005. URL: http://dx.doi.org/10.1042/bj20041577, doi:10.1042/bj20041577. This article has 65 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20041577)

[4. (Garg2007SpermAssociated) Manoj Garg, Dipak Chaurasiya, Ritu Rana, Nirmala Jagadish, Deepika Kanojia, Namrata Dudha, Neha Kamran, Sudha Salhan, Amar Bhatnagar, Sushma Suri, Anju Gupta, and Anil Suri. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clinical Cancer Research, 13(5):1421–1428, March 2007. URL: http://dx.doi.org/10.1158/1078-0432.ccr-06-2340, doi:10.1158/1078-0432.ccr-06-2340. This article has 57 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-06-2340)

[5. (YANG2015SPAG9) XIAORONG YANG, WENLAI ZHOU, and SHIQING LIU. Spag9 controls the cell motility, invasion and angiogenesis of human osteosarcoma cells. Experimental and Therapeutic Medicine, 11(2):637–644, December 2015. URL: http://dx.doi.org/10.3892/etm.2015.2932, doi:10.3892/etm.2015.2932. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/etm.2015.2932)

[6. (Garg2009Small) Manoj Garg, Deepika Kanojia, Sushma Suri, and Anil Suri. Small interfering rna‐mediated down‐regulation of spag9 inhibits cervical tumor growth. Cancer, 115(24):5688–5699, October 2009. URL: http://dx.doi.org/10.1002/cncr.24658, doi:10.1002/cncr.24658. This article has 24 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/cncr.24658)

[7. (Li2020Sperm) Wan Li, Fei Wang, Jiale Shi, Qi Feng, Yuheng Chen, Xiaoyu Qi, Cong Wang, Hongmei Lu, Zhongmou Lu, Xuemei Jia, Qin Yan, Shou-Jiang Gao, and Chun Lu. Sperm associated antigen 9 promotes oncogenic kshv-encoded interferon regulatory factor-induced cellular transformation and angiogenesis by activating the jnk/vegfa pathway. PLOS Pathogens, 16(8):e1008730, August 2020. URL: http://dx.doi.org/10.1371/journal.ppat.1008730, doi:10.1371/journal.ppat.1008730. This article has 10 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.ppat.1008730)

[8. (Garg2009Sperm‐associated) Manoj Garg, Deepika Kanojia, Sudha Salhan, Sushma Suri, Anju Gupta, Nirmal Kumar Lohiya, and Anil Suri. Sperm‐associated antigen 9 is a biomarker for early cervical carcinoma. Cancer, 115(12):2671–2683, June 2009. URL: http://dx.doi.org/10.1002/cncr.24293, doi:10.1002/cncr.24293. This article has 48 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/cncr.24293)